Published in Drug Law Weekly, June 29th, 2004
Both product candidates are under FDA review for marketing clearance.
"We are delighted to have completed these two successful FDA PAI of our manufacturing facility without receiving a Form 483, which is the document used by FDA investigators to record observations of noncompliance with current good...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.